Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment

NCT02926859 is registered in ClinicalTrials.gov with Central Institute of Mental Health, Mannheim as lead sponsor.

NCT NCT02926859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment
Lead sponsor
Central Institute of Mental Health, Mannheim
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 8, 2017
Completion date
December 31, 2027
Enrollment
180 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia